Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Neurochem ; 120(4): 564-73, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21950964

RESUMO

Focal cerebral cortical infarction after distal middle cerebral artery occlusion causes ß-amyloid deposition and secondary neuronal degeneration in the ipsilateral ventroposterior nucleus of the thalamus. Several studies suggest that autophagy is an active pathway for ß-amyloid peptide generation. This study aimed to investigate the role of autophagy in thalamic ß-amyloid deposition and neuronal degeneration after cerebral cortical infarction in hypertensive rats. At 7 and 14days after middle cerebral artery occlusion, neuronal death and ß-amyloid deposits were evident in the ipsilateral ventroposterior nucleus, and the activity of ß-site amyloid precursor protein (APP)-cleaving enzyme 1, required for ß-amyloid peptide generation, was elevated in the thalamus. In correlation, both the number of cells showing punctate microtubule-associated protein 1A light chain 3 fluorescence and levels of light chain 3-II protein, an autophagosome marker, were markedly increased. Notably, most of the cells that over-expressed ß-site APP-cleaving enzyme 1 displayed punctate light chain 3 staining. Furthermore, the inhibition of autophagy with 3-methyladenine significantly reduced the thalamic neuronal damage, ß-amyloid deposits, and ß-site APP-cleaving enzyme 1 activity. These results suggest that autophagosomes accumulate within thalamic cells after cerebral cortical infarction, which is associated with thalamic ß-amyloid deposition and secondary neuronal degeneration via elevation of ß-site APP-cleaving enzyme 1 level.


Assuntos
Peptídeos beta-Amiloides/metabolismo , Autofagia/fisiologia , Infarto Cerebral/patologia , Hipertensão/patologia , Fagossomos/patologia , Placa Amiloide/patologia , Tálamo/patologia , Secretases da Proteína Precursora do Amiloide/biossíntese , Secretases da Proteína Precursora do Amiloide/fisiologia , Peptídeos beta-Amiloides/fisiologia , Animais , Ácido Aspártico Endopeptidases/biossíntese , Ácido Aspártico Endopeptidases/fisiologia , Infarto Cerebral/enzimologia , Infarto Cerebral/metabolismo , Hipertensão/enzimologia , Hipertensão/metabolismo , Masculino , Degeneração Neural/enzimologia , Degeneração Neural/metabolismo , Degeneração Neural/patologia , Fagossomos/enzimologia , Fagossomos/metabolismo , Placa Amiloide/enzimologia , Placa Amiloide/metabolismo , Ratos , Ratos Sprague-Dawley , Tálamo/enzimologia , Tálamo/metabolismo
2.
Cell Immunol ; 259(1): 1-4, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19560127

RESUMO

CpG oligodeoxynucleotides have been previously shown to enhance antimycobacterial response in human monocytes/macrophages. The present study reports evidences showing the capability of CpG oligodeoxynucleotides to induce (i) host phospholipase D (PLD) activation, (ii) PLD dependent reactive oxygen intermediate production, (iii) PLD dependent phagolysosome maturation and (iv) PLD dependent intracellular mycobacterial killing in type II alveolar epithelial cells. These are the first evidences showing that alveolar epithelial cells may represent efficient effecter cells during primary innate antimycobacterial immune response.


Assuntos
Adjuvantes Imunológicos/farmacologia , Mycobacterium tuberculosis/imunologia , Oligodesoxirribonucleotídeos/farmacologia , Fosfolipase D/efeitos dos fármacos , Alvéolos Pulmonares/efeitos dos fármacos , Mucosa Respiratória/efeitos dos fármacos , Linhagem Celular Tumoral , Humanos , Fagossomos/efeitos dos fármacos , Fagossomos/enzimologia , Fagossomos/microbiologia , Fosfolipase D/biossíntese , Alvéolos Pulmonares/imunologia , Alvéolos Pulmonares/microbiologia , Mucosa Respiratória/imunologia , Mucosa Respiratória/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA